PureTech Health Plcの機関の所有権
PureTech Health Plcの機関の所有権は何ですか。
PureTech Health Plcの機関の所有権は71.66%です。
機関の所有権の定義は何ですか。
機関所有権は、ミューチュアル・ファンドまたは年金基金、保険会社、投資会社、その他の資金を管理する他の団体が所有する会社の株式数です。
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
LSEのセクタHealth Careにおける機関の所有権の企業と比べるPureTech Health Plc
PureTech Health Plcは何をしますか。
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health Plcと類似の機関の所有権
- Kinross Goldの機関の所有権は71.58%です。
- M & T Bank Corpの機関の所有権は71.60%です。
- Chevronの機関の所有権は71.60%です。
- IG Plcの機関の所有権は71.62%です。
- Rocket Companiesの機関の所有権は71.63%です。
- Tabula Rasa HealthCare Incの機関の所有権は71.64%です。
- PureTech Health Plcの機関の所有権は71.66%です。
- Lennox International Incの機関の所有権は71.68%です。
- Amtech Systemsの機関の所有権は71.68%です。
- Morgan Sindall plcの機関の所有権は71.68%です。
- BlackRock Enhanced Government Fund Incの機関の所有権は71.69%です。
- NavSightの機関の所有権は71.69%です。
- Whole Earth Brandsの機関の所有権は71.69%です。